Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,508,886 papers from all fields of science
Search
Sign In
Create Free Account
vidofludimus
Known as:
2-(3-fluoro-3'-methoxybiphenyl-4-carbamoyl)cyclopent-1-enecarboxylic acid
, 4SC-101
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Biphenyl Compounds
Dicarboxylic Acids
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
A. Muehler
,
H. Kohlhof
,
M. Groeppel
,
D. Vitt
European Journal of Drug Metabolism and…
2020
Corpus ID: 218466762
Background and Objective Vidofludimus is a potent and selective inhibitor of human mitochondrial enzyme dihydroorotate…
Expand
2020
2020
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
A. Muehler
,
E. Peelen
,
H. Kohlhof
,
Manfred Gröppel
,
D. Vitt
Multiple sclerosis and related disorders
2020
Corpus ID: 218759881
2020
2020
Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD
Yanlin Zhu
,
Shuangshuang Xu
,
+8 authors
Yong Li
Frontiers in Pharmacology
2020
Corpus ID: 218616499
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder, and yet with no pharmacological…
Expand
2019
2019
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
A. Muehler
,
H. Kohlhof
,
M. Groeppel
,
D. Vitt
Drugs in R&D
2019
Corpus ID: 204707294
The dihydroorotate dehydrogenase (DHODH) inhibitors leflunomide and teriflunomide are immunomodulatory agents approved to treat…
Expand
Highly Cited
2013
Highly Cited
2013
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
K. Herrlinger
,
M. Diculescu
,
+14 authors
E. Stange
Journal of Crohn's & colitis
2013
Corpus ID: 21252325
2012
2012
Vidofludimus Inhibits Colonic Interleukin-17 and Improves Hapten-Induced Colitis in Rats by a Unique Dual Mode of Action
L. Fitzpatrick
,
Jeffrey S. Small
,
R. Doblhofer
,
A. Ammendola
Journal of Pharmacology and Experimental…
2012
Corpus ID: 24927906
Vidofludimus (Vido) is a novel oral immunomodulatory drug that inhibits dihydro-orotate dehydrogenase and lymphocyte…
Expand
2012
2012
Immunosuppression With 4SC-101, a Novel Inhibitor of Dihydroorotate Dehydrogenase, in a Rat Model of Renal Transplantation
K. Rusai
,
C. Schmaderer
,
+9 authors
U. Heemann
Transplantation
2012
Corpus ID: 27943817
Background 4SC-101 is a novel dihydroorotate dehydrogenase inhibitor and a blocker of interleukin (IL)-17 secretion with…
Expand
Highly Cited
2010
Highly Cited
2010
4SC‐101, a novel immunosuppressive drug, inhibits IL‐17 and attenuates colitis in two murine models of inflammatory bowel disease†
L. Fitzpatrick
,
L. Deml
,
+6 authors
A. Ammendola
Inflammatory bowel diseases
2010
Corpus ID: 1598491
Background: Dihydroorotate dehydrogenase (DHODH) is a key enzyme involved in pyrimidine biosynthesis. DHODH is a known target for…
Expand
Highly Cited
2010
Highly Cited
2010
4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
O. Kulkarni
,
S. Sayyed
,
+8 authors
H. Anders
The American journal of pathology
2010
Corpus ID: 10636882
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better…
Expand
2010
2010
Immunopathology and Infectious Diseases 4 SC-101 , A Novel Small Molecule Dihydroorotate Dehydrogenase Inhibitor , Suppresses Systemic Lupus Erythematosus in MRL-( Fas ) lpr Mice
O. Kulkarni
,
S. Sayyed
,
+8 authors
H. Anders
2010
Corpus ID: 19145706
Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE